

GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032

<https://marketpublishers.com/r/G6B520954B7EEN.html>

Date: July 2024

Pages: 316

Price: US\$ 3,217.50 (Single User License)

ID: G6B520954B7EEN

Abstracts

The GLP-1 Analogues market is expected to reach USD 471.1 billion by 2032 from USD 47.4 billion in 2024, at a CAGR of 33.2% during the forecast period. The key factors driving the growth of the GLP-1 Analogues market include the growing popularity of the GLP-1 drug class for the treatment of chronic obesity and weight management and high efficacy of GLP-1 analogues for treating type 2 diabetes. Additionally, innovation focusing on the development of convenient forms of GLP-1 drugs, such as oral dosage forms and single dose autoinjectors, are expected to drive growth of GLP-1 analogues market.

The GLP-1 Analogues market has been segmented based on products, format, route of administration, indication, and end-user.

“By product, Zepbound (tirzepatide) drug is forecasted to grow at the fastest rate in the GLP-1 Analogues market”

Based on product, the GLP-1 Analogues market is categorized into Ozempic (semaglutide), Trulicity (dulaglutide), Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide [rDNA origin] injection), Victoza (liraglutide), Xultophy 100/3.6 (insulin degludec and liraglutide injection), Soliqua 100/33 (insulin glargine and lixisenatide injection), Zepbound (tirzepatide), Bydureon (exenatide extended-release), and other products. Zepbound is expected to experience fastest growth during the forecast period owing to factors such as approval of the drug for the

treatment of obesity, exponential revenue growth observed since launch of the drug in 2023, and growing adoption of tirzepatide for obesity and weight management.

“By product format, the single dose format segment accounted for the largest share in the GLP-1 Analogues market”

Based on product format, the GLP-1 Analogues market is segmented into single-dose, multi-dose, and tablets. In 2023, the single-dose format segment accounted for the largest share of the GLP-1 Analogues market. Growth in this market segment can be attributed to the ease of administration and lower injection frequencies offered by single-dose format, together with the growing availability of single-dose auto-injectors.

“North America: accounted for the largest share of the GLP-1 Analogues market”

North America accounted for the largest share of the GLP-1 Analogues market. The large share of the North American region can be attributed to growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of GLP-1 products in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include Eli Lilly and Company (US), Novo Nordisk A/S (Denmark).

“Europe: The second-largest region in the GLP-1 Analogues market.”

The Europe GLP-1 Analogues market is the second largest market for GLP-1 Analogue drugs. This is attributed to the presence of a large number of academic and research institutes in this region, growing investments by market players and government institutes, and an increasing focus on research and development activities.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%

By Designation: Managers - 45%, Directors- 30%, and Executives - 25%

By Country: North America- 40%, Europe- 30%, Asia Pacific- 20%, Latin America- 5%, and Middle East and Africa- 5%

Prominent Players

Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), AstraZeneca (UK), Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (China), Boehringer Ingelheim International GmbH (Germany), Innovent (China), Paige Biopharmaceutical (Suzhou) Co., Ltd. (China), Sciwind Biosciences Co., Ltd. (China), Zealand Pharma A/S (Denmark), Beijing Dongfang Baitai Biotechnology Co., Ltd (China), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)

Research Coverage:

This report provides a detailed picture of the GLP-1 Analogues market. It aims to estimate the size and future growth potential of the market across different segments, such as the product, product format, route of administration, indication, end user, and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the GLP-1 Analogues market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provides insights on the following pointers”

Analysis of key drivers (Strong R&D pipeline, Improved relative efficacy of GLP-1 drugs), opportunities (Integration of GLP-1 drugs into telehealth and digital weight management programs), restraints (High barriers for new entrants due to duopoly), and challenges (Off-label use of GLP-1 drugs, High non-adherence to therapy after 12-24 months) influencing the growth of the GLP-1 Analogues market.

Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the GLP-1

Analogues market.

Market Development: Comprehensive information about lucrative markets- the report analyses the GLP-1 Analogues market across varied regions.

Market Diversification: Exhaustive information about new drugs, untapped geographies, recent developments, and investments in the GLP-1 Analogues market.

Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
 - 1.2.1 INCLUSIONS & EXCLUSIONS
- 1.3 MARKET SCOPE
 - 1.3.1 MARKETS COVERED
 - 1.3.2 REGIONS COVERED
 - 1.3.3 YEARS CONSIDERED
 - 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 RECESSION IMPACT

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.2 PRIMARY DATA
- 2.2 MARKET SIZE ESTIMATION
 - 2.2.1 MARKET SIZE ASSESSMENT
- 2.3 MARKET GROWTH FORECAST
- 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 LIMITATIONS
- 2.7 RISK ANALYSIS
- 2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 GLP-1 ANALOGUES MARKET OVERVIEW
- 4.2 NORTH AMERICA: GLP-1 ANALOGUES MARKET SHARE, BY INDICATION AND COUNTRY (2023)
- 4.3 GLP-1 ANALOGUES MARKET SHARE, BY PRODUCT, 2024 VS. 2032
- 4.4 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION, 2023
- 4.5 GLP-1 ANALOGUES MARKET SHARE, BY END USER, 2024 VS. 2032

4.6 GLP-1 ANALOGUES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 Strong R&D pipeline

5.2.1.2 Improved relative efficacy of GLP-1 drugs

5.2.1.3 High demand, expanding insurance coverage, growing sales, increasing awareness, and positive outcomes

5.2.2 RESTRAINTS

5.2.2.1 High barriers for new entrants due to duopoly

5.2.3 OPPORTUNITIES

5.2.3.1 Extended therapeutic uses

5.2.3.2 Integration of GLP-1 drugs into telehealth and digital weight management programs

5.2.4 CHALLENGES

5.2.4.1 Off-label use of GLP-1 drugs

5.2.4.2 High non-adherence to therapy after 12–24 months

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

5.4 PRICING ANALYSIS

5.4.1 AVERAGE SELLING PRICE TREND OF GLP-1 ANALOGUES

5.4.2 AVERAGE SELLING PRICES OF TOP GLP-1 ANALOGUES, BY COUNTRY/REGION

5.5 TECHNOLOGY ANALYSIS

5.5.1 KEY TECHNOLOGIES

5.5.1.1 Chemical Synthesis

5.5.1.2 Recombinant DNA Technology

5.5.2 ADJACENT TECHNOLOGIES

5.5.2.1 Hydrogel Depot Technology

5.5.2.2 Technologies for oral delivery of GLP-1 analogues

5.6 PIPELINE ANALYSIS

5.7 TRADE DATA

5.8 PATENT ANALYSIS

5.8.1 METHODOLOGY

5.8.2 INNOVATION AND PATENT APPLICATIONS

5.8.3 TOP APPLICANTS

5.9 VALUE CHAIN ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS

5.11 ECOSYSTEM ANALYSIS

5.11.1 GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS

5.11.2 GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES

5.11.3 GLP-1 ANALOGUES MARKET: ROLE OF END USERS

5.11.4 GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES

5.12 PORTER'S FIVE FORCES ANALYSIS

5.12.1 THREAT OF NEW ENTRANTS

5.12.2 THREAT OF SUBSTITUTES

5.12.3 BARGAINING POWER OF SUPPLIERS

5.12.4 BARGAINING POWER OF BUYERS

5.12.5 INTENSITY OF COMPETITIVE RIVALRY

5.13 KEY STAKEHOLDERS AND BUYING CRITERIA

5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS

5.13.2 BUYING CRITERIA FOR GLP-1 ANALOGUES

5.14 REGULATORY LANDSCAPE

5.14.1 REGULATORY SCENARIO

5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.14.2.1 North America

5.14.2.2 Europe

5.14.2.3 Asia Pacific

5.14.2.4 Rest of the World

5.15 KEY CONFERENCES & EVENTS, 2024–2025

5.16 CASE STUDIES

5.16.1 STUDY OF TIRZEPATIDE AS A CASE IN GLP-1 DRUGS MARKET

5.16.2 OZEMPIC OFF-LABEL USE

5.17 INVESTMENT AND FUNDING SCENARIO

6 GLP-1 ANALOGUES MARKET, BY PRODUCT

6.1 INTRODUCTIONS

6.2 OZEMPIC

6.2.1 RISING ADOPTION TO SUPPORT MARKET GROWTH

6.3 TRULICITY

6.3.1 COMPETITOR REVENUE GROWTH TO AFFECT GROWTH

6.4 MOUNJARO

6.4.1 EXPONENTIAL GROWTH ANTICIPATED DUE TO HIGH ADOPTION IN

NORTH AMERICA

6.5 WEGOVY

6.5.1 INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT GROWTH

6.6 RYBELSUS

6.6.1 CONVENIENCE OF ORAL ADMINISTRATION TO DRIVE MARKET

6.7 SAXENDA

6.7.1 DEVELOPMENT OF GENERIC VERSIONS TO SLOW GROWTH

6.8 VICTOZA

6.8.1 ADOPTION OF ORAL GLP-1S TO RESTRAIN MARKET GROWTH

6.9 XULTOPHY

6.9.1 REGULATORY APPROVALS TO SUPPORT MARKET GROWTH

6.1 SOLIQUA

6.10.1 COMPETITOR GLP-1 PRODUCTS THREAT TO GROWTH

6.11 ZEPBOUND

6.11.1 STRONG REVENUE GROWTH TO ENSURE CONTINUED PRESENCE

6.12 BYDUREON

6.12.1 COMPETITOR PRODUCTS TO AFFECT MARKET GROWTH

6.13 OTHER PRODUCTS

7 GLP-1 ANALOGUES MARKET, BY FORMAT

7.1 INTRODUCTIONS

7.2 SINGLE DOSE

7.2.1 HIGH ADOPTION DUE TO EASE OF ADMINISTRATION TO SUPPORT GROWTH

7.3 MULTI-DOSE

7.3.1 LOW COST TO ATTRACT LARGER ADOPTION

7.4 TABLETS

7.4.1 DEVELOPMENT OF HIGH-POTENCY GLP-1S TO SUPPORT MARKET GROWTH

8 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION

8.1 INTRODUCTION

8.2 SUBCUTANEOUS ADMINISTRATION

8.2.1 PEN INJECTORS

8.2.1.1 Ease of monitoring to support adoption

8.2.2 AUTOINJECTORS

8.2.2.1 Advantages offered over pen injectors to support adoption

8.3 ORAL ADMINISTRATION

8.3.1 ELIMINATION OF NEEDLE PHOBIA AND EASE OF USE TO DRIVE COMPLIANCE

9 GLP-1 ANALOGUES MARKET, BY INDICATION

9.1 INTRODUCTION

9.2 DIABETES

9.2.1 HIGH EFFICACY TO SUPPORT MARKET GROWTH

9.3 OBESITY

9.3.1 INCREASING DEMAND AND PIPELINE FOCUS ON ANTI-OBESITY GLP-1S TO DRIVE MARKET

9.4 OTHER INDICATIONS

10 GLP-1 ANALOGUES MARKET, BY END USER

10.1 INTRODUCTIONS

10.2 HOME CARE SETTINGS

10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH

10.3 LONG-TERM CARE FACILITIES

10.3.1 GROWING GERIATRIC POPULATION AND RISING CHRONIC DISEASE INCIDENCE TO DRIVE MARKET

10.4 HOSPITALS & SPECIALTY CLINICS

10.4.1 ADOPTION OF GLP-1 FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH

11 GLP-1 ANALOGUES MARKET, BY REGION

11.1 INTRODUCTION

11.2 NORTH AMERICA

11.2.1 NORTH AMERICA: RECESSION IMPACT

11.2.2 US

11.2.2.1 Strategic developments by major players and R&D activities to drive market

11.2.3 CANADA

11.2.3.1 Strong research infrastructure and availability of funding to support market growth

11.3 EUROPE

11.3.1 EUROPE: RECESSION IMPACT

11.3.2 GERMANY

11.3.2.1 Improving accessibility to support market growth in Germany

11.3.3 UK

11.3.3.1 Increasing research to evaluate efficacy and potential of GLP-1 analogues to support market growth

11.3.4 FRANCE

11.3.4.1 Growing awareness to propel market growth

11.3.5 ITALY

11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market

11.3.6 SPAIN

11.3.6.1 Favorable initiatives for research to drive market

11.3.7 NETHERLANDS

11.3.7.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth

11.3.8 REST OF EUROPE

11.4 ASIA PACIFIC

11.4.1 ASIA PACIFIC: RECESSION IMPACT

11.4.2 CHINA

11.4.2.1 Expansion of major biotechnology and pharmaceutical companies in China to drive market

11.4.3 JAPAN

11.4.3.1 Growing availability of prominent GLP-1 drugs to drive market

11.4.4 INDIA

11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth

11.4.5 AUSTRALIA

11.4.5.1 Access to GLP-1 drugs and government support to drive market

11.4.6 SOUTH KOREA

11.4.6.1 Collaborations in obesity drugs to propel market growth

11.4.7 REST OF ASIA PACIFIC

11.5 LATIN AMERICA

11.5.1 LATIN AMERICA: RECESSION IMPACT

11.5.2 BRAZIL

11.5.2.1 Brazil to hold largest market share in Latin America

11.5.3 MEXICO

11.5.3.1 Growing diabetes and obesity cases to support market growth

11.5.4 REST OF LATIN AMERICA

11.6 MIDDLE EAST

11.6.1 MIDDLE EAST: RECESSION IMPACT

11.6.2 GCC COUNTRIES

11.6.2.1 Saudi Arabia

11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth

11.6.2.2 UAE

11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to support market growth

11.6.2.3 Rest of GCC countries

11.6.3 REST OF MIDDLE EAST

11.7 AFRICA

11.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH

11.7.2 AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 KEY PLAYER STRATEGY/RIGHT TO WIN

12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 ANALOGUES MARKET

12.3 REVENUE ANALYSIS

12.4 MARKET SHARE ANALYSIS

12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023

12.5.1 STARS

12.5.2 EMERGING LEADERS

12.5.3 PERVASIVE PLAYERS

12.5.4 PARTICIPANTS

12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023

12.6.1 STARS

12.6.2 EMERGING LEADERS

12.6.3 PERVASIVE PLAYERS

12.6.4 PARTICIPANTS

12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023

12.6.5.1 Company Footprint

12.6.5.2 Format footprint

12.6.5.3 Route of administration footprint

12.6.5.4 Indication footprint

12.6.5.5 Region footprint

12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023

- 12.7.1 PROGRESSIVE COMPANIES
- 12.7.2 RESPONSIVE COMPANIES
- 12.7.3 DYNAMIC COMPANIES
- 12.7.4 STARTING BLOCKS
- 12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 12.8 VALUATION & FINANCIAL METRICS
 - 12.8.1 FINANCIAL METRICS
 - 12.8.2 COMPANY VALUATION
- 12.9 BRAND/PRODUCT COMPARISON
- 12.1 COMPETITIVE SCENARIO
 - 12.10.1 PRODUCT APPROVALS
 - 12.10.2 DEALS
 - 12.10.3 EXPANSIONS
 - 12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

- 13.1 INTRODUCTION
- 13.2 KEY PLAYERS
 - 13.2.1 NOVO NORDISK A/S
 - 13.2.1.1 Business overview
 - 13.2.1.2 Products offered
 - 13.2.1.3 Recent developments
 - 13.2.1.3.1 Product approvals
 - 13.2.1.3.2 Expansions
 - 13.2.1.3.3 Other developments
 - 13.2.1.4 MnM view
 - 13.2.1.4.1 Right to win
 - 13.2.1.4.2 Strategic choices
 - 13.2.1.4.3 Weaknesses & competitive threats
 - 13.2.2 ELI LILLY AND COMPANY
 - 13.2.2.1 Business overview
 - 13.2.2.2 Products offered
 - 13.2.2.3 Recent developments
 - 13.2.2.3.1 Product approvals
 - 13.2.2.3.2 Deals
 - 13.2.2.3.3 Expansions
 - 13.2.2.4 MnM view
 - 13.2.2.4.1 Right to win

- 13.2.2.4.2 Strategic choices
- 13.2.2.4.3 Weaknesses & competitive threats
- 13.2.3 SANOFI
 - 13.2.3.1 Business overview
 - 13.2.3.2 Products offered
 - 13.2.3.3 MnM view
 - 13.2.3.3.1 Key strengths
 - 13.2.3.3.2 Strategic choices
 - 13.2.3.3.3 Weaknesses & competitive threats
- 13.2.4 ASTRAZENECA
 - 13.2.4.1 Business overview
 - 13.2.4.2 Products offered
 - 13.2.4.3 Recent developments
 - 13.2.4.3.1 Product approvals
 - 13.2.4.4 MnM view
 - 13.2.4.4.1 Right to win
 - 13.2.4.4.2 Strategic choices
 - 13.2.4.4.3 Weaknesses & competitive threats
- 13.2.5 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
 - 13.2.5.1 Business overview
 - 13.2.5.2 Products offered
- 13.2.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
 - 13.2.6.1 Business overview
 - 13.2.6.2 Products in pipeline
 - 13.2.6.3 Recent developments
 - 13.2.6.3.1 Deals
 - 13.2.6.3.2 Other developments
- 13.2.7 INNOVENT
 - 13.2.7.1 Business overview
 - 13.2.7.2 Products in pipeline
 - 13.2.7.3 Recent developments
 - 13.2.7.3.1 Other developments
- 13.2.8 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
 - 13.2.8.1 Business overview
 - 13.2.8.2 Products in pipeline
- 13.2.9 SCIWIND BIOSCIENCES CO., LTD.
 - 13.2.9.1 Business overview
 - 13.2.9.2 Products in pipeline
 - 13.2.9.3 Recent developments

- 13.2.9.3.1 Deals
- 13.2.9.3.2 Other developments
- 13.2.10 ZEALAND PHARMA A/S
 - 13.2.10.1 Business overview
 - 13.2.10.2 Products in pipeline
 - 13.2.10.3 Recent developments
 - 13.2.10.3.1 Deals
 - 13.2.10.3.2 Other developments
- 13.2.11 BEIJING DONGFANG BAITAI BIOTECHNOLOGY CO., LTD (EASTERN BIOTECH)
 - 13.2.11.1 Business overview
 - 13.2.11.2 Products in pipeline
- 13.3 OTHER PLAYERS
 - 13.3.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
 - 13.3.2 VTV THERAPEUTICS
 - 13.3.3 TERNS PHARMACEUTICALS, INC.
 - 13.3.4 ALTIMMUNE
 - 13.3.5 SCOHIA PHARMA, INC.
 - 13.3.6 STRUCTURE THERAPEUTICS
 - 13.3.7 NEUROBO PHARMACEUTICALS, INC.
 - 13.3.8 I2O THERAPEUTICS, INC.
 - 13.3.9 AMGEN INC.
 - 13.3.10 PFIZER INC.
 - 13.3.11 MERCK & CO., INC.
 - 13.3.12 HANMI PHARM CO., LTD.
 - 13.3.13 VIKING THERAPEUTICS
 - 13.3.14 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

14 APPENDIX

- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS

I would like to order

Product name: GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032

Product link: <https://marketpublishers.com/r/G6B520954B7EEN.html>

Price: US\$ 3,217.50 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6B520954B7EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970